TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05990257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HHB+TAPB+and LA
Description: Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HHB+LA
Description: Hepatic Hilar Block (HHB) and Local Anesthesia (LA)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAPB+LA
Description: Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)
Study: NCT03525613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: Complement (C3) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: Complement (C3) Inhibitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Subjects will receive a Sham procedure every month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Subjects will receive a Sham procedure every other month
Study: NCT01317368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropine
Description: 20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropine
Description: 20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
Study: NCT03925493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exercise Stress test (GXT) with Target Heart Rate Range
Description: Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exercise Stress test (GXT) with Target Heart Rate Range
Description: Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate monitors
Description: Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
Study: NCT01322711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40 mg day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diet
Study: NCT02528461

Intervention type: DRUG
Intervention: Galactose
Description: A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.

Intervention type: PROCEDURE
Intervention: Gastroscopy

Intervention type: PROCEDURE
Intervention: Liver biopsy

Intervention type: PROCEDURE
Intervention: Fibroscan

Intervention type: PROCEDURE
Intervention: Liver vein catheterization

Intervention type: DRUG
Intervention: Sofosbuvir
Study: NCT01920061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384 (gedatolisib)
Description: PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384 (gedatolisib)
Description: PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384 (gedatolisib)
Description: PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384 (gedatolisib)
Description: PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384 (gedatolisib)
Description: PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
Study: NCT01844310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAL+TDF+LPV/r
Description: Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC+TDF+LPV/r
Description: Group B will be assigned with 3TC+TDF+LPV/r
Study: NCT00412425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: 0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: 0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
Study: NCT00740766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food diary and behavioral model
Description: The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study.
Study: NCT04439708

Intervention type: OTHER
Intervention: Blood and aqueous humor biomarker of treatment response
Description: Blood analyses and aqueous humor analysis

Intervention type: OTHER
Intervention: Blood and aqueous humor biomarker of treatment response
Description: Blood analyses and aqueous humor analysis
Study: NCT01756482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5806
Description: GS-5806, powder for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00283062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (TAXOTERE®) Chemotherapy
Description: 75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
Study: NCT02072525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menveo®
Description: One dose administered intramuscularly (IM) in the upper left deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menveo®
Description: One dose administered intramuscularly (IM) in the upper left deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the upper right deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the upper right deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the upper right deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23®
Description: One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23®
Description: One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23®
Description: One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13®
Description: One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13®
Description: One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13®
Description: One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
Study: NCT04407065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double trigger
Description: Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG trigger
Description: Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Study: NCT01199276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
Study: NCT01709201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
Study: NCT02537405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939)
Description: Rivaroxaban granule 10mg for one day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Rivaroxaban tablet 10mg for one day
Study: NCT02326766

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KRG
Description: 5g Korea red ginseng (KRG)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5g placebo
Study: NCT00568113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine in arm 1
Description: Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylcysteine in arm 1
Description: Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy.
Study: NCT03805516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCOPP-CW
Description: The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
Study: NCT02562274

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are received placebo treatments once daily for 8 weeks
Study: NCT03909451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02562274

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MP 50 mg/day
Description: Subjects are received MP 50 mg/day treatments once daily for 8 weeks
Study: NCT03909451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00955149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Description: Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Description: Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
Study: NCT02610933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban
Description: replacement of vitamin K antagonist by rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban
Description: replacement of vitamin K antagonist by rivaroxaban

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2
Description: Vitamin K2 supplementation
Study: NCT00997620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate Nasal Spray 110 mcg
Description: Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
Study: NCT01281228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide + exendin (9-39)
Description: The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline infusion
Study: NCT00506194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAD
Description: Gliclazide-MR, Metformin, Glimepiride
Study: NCT04254029

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MOROLSTEVER1
Description: The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
Study: NCT04264143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusate with MTX110 and gadolinium
Description: Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Convection-Enhanced Delivery (CED)
Description: CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
Study: NCT00599456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid vitamins
Description: Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules,2 capsules, by mouth, daily for 3 months
Study: NCT04008511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid po for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid po for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid po for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2, day 1, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2, day 1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2, day 1, every 3 weeks
Study: NCT02554214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glafkos drainage device
Study: NCT01896271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation Therapy
Description: SABR dose varying from 8Gy-20Gy in 1-3 fractions
Study: NCT01824706

Intervention type: PROCEDURE
Intervention: craniectomy
Description: craniectomy
Study: NCT02700594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint mobilization
Description: Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint mobilization
Description: Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings.
Study: NCT00665236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy
Description: Eight weekly 45-minute sessions with therapist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low strength static magnets
Description: Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
Study: NCT03255759

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multiplex molecular diagnostic assay
Description: To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.